Merck & Co. does not anticipate significant effects from the new US tariffs against Canada, Mexico and China, but it is facing a challenge with sales of the human papillomavirus (HPV) vaccine Gardasil, as the company withdrew its 2030 revenue target amid continuing demand issues in China and paused shipments to its commercialization partner there. Meanwhile, Merck expects a $400m impact from the Medicare Part D redesign under the Inflation Reduction Act.
Merck Drops 2030 Sales Target For Gardasil As China Slump Continues
Significant Tariff Impact Is Unlikely
The drug maker withdrew its goal of $11bn in sales for the HPV vaccine and paused shipments to China so that partner Zhifei can reduce its inventory.
More from Earnings
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.
• By
Obefazimod has been heralded as a potential blockbuster for ulcerative colitis and there will be great interest in the readout of Phase III induction trials in the third quarter of this year.
More from Therapy Areas
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus